Enadenotucirev is a clinical stage oncolytic virus therapeutic with broad potential to target solid tumor carcinomas. Delivery of enadenotucirev to tumors has been demonstrated in the clinic following intravenous administration, giving enadenotucirev the potential for systemic treatment of cancers.
Enadenotucirev is currently in clinical studies in the USA and Europe. The OCTAVE study combines enadenotucirev with paclitaxel for the treatment of advanced ovarian cancer. The SPICE study combines enadenotucirev with nivolumab in multiple solid tumors, in a clinical trial collaboration with Bristol-Myers Squibb.
Enadenotucirev is a non-naturally occurring Group B adenovirus developed using the principle of directed evolution to generate a virus with cancer killing activity and stability in blood, thus permitting intravenous delivery (Figure 1). Enadenotucirev was also selected to replicate only in tumor tissue and not within normal, non-cancerous tissue.
Clinical studies have established that enadenotucirev can be delivered intravenously and will reach and replicate in both primary and metastatic tumors, with no evidence of replication in non-cancerous cells. Clinical evidence of intravenous delivery importantly differentiates enadenotucirev from other oncolytic viruses.
Enadenotucirev is anticipated to be capable of destroying tumor cells and at the same time attracting cells of the immune system to drive anti-tumor immunity and potentially make the tumor more susceptible to other treatments, including both chemotherapy and immunotherapy.
Enadenotucirev forms the basis of and acts as an adenoviral delivery vector for our next generation oncolytic gene therapy virus platform, Tumor-Specific Immuno-Gene Therapy (T-SIGn).
View clinical trials with Enadenotucirev.